Sutro Biopharma (NASDAQ:STRO) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Sutro Biopharma (NASDAQ:STRO) from an equal weight rating to an overweight rating in a report issued on Tuesday morning, Marketbeat.com reports. They currently have $27.00 price target on the stock, up from their prior price target of $8.00.

A number of other brokerages also recently weighed in on STRO. Wedbush reissued a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research note on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Finally, HC Wainwright upgraded Sutro Biopharma from a “neutral” rating to a “buy” rating and boosted their price target for the company from $10.00 to $28.00 in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $37.29.

Sutro Biopharma Trading Up 6.0%

Shares of Sutro Biopharma stock opened at $24.91 on Tuesday. Sutro Biopharma has a 1 year low of $5.23 and a 1 year high of $26.54. The company’s fifty day simple moving average is $18.84 and its 200-day simple moving average is $12.84. The company has a market cap of $212.08 million, a price-to-earnings ratio of -0.95 and a beta of 1.47.

Hedge Funds Weigh In On Sutro Biopharma

A number of hedge funds have recently made changes to their positions in the business. Bridgeway Capital Management LLC lifted its holdings in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after acquiring an additional 30,000 shares during the period. Invesco Ltd. increased its stake in Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares during the period. Cerity Partners LLC increased its stake in Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the period. Qube Research & Technologies Ltd acquired a new position in Sutro Biopharma in the second quarter worth about $82,000. Finally, State of Tennessee Department of Treasury acquired a new position in Sutro Biopharma in the fourth quarter worth about $86,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Key Headlines Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target to $55 from $51 and maintained a “Buy” rating — a sizable upside vs. the current price, which supports bullish sentiment. Benzinga
• Positive Sentiment: Truist Financial upgraded Sutro to “Strong-Buy,” reinforcing buy-side momentum among institutional analysts. Zacks
• Positive Sentiment: Wells Fargo upgraded STRO to “Overweight,” adding another supportive brokerage view that can attract investors. Wells Fargo Upgrade
• Positive Sentiment: HC Wainwright also issued an upgrade/coverage item (Buy, $28 PT) in recent press coverage, adding to the cluster of buy-side recommendations. AmericanBankingNews – HC Wainwright Upgrade
• Neutral Sentiment: HC Wainwright published a FY2030 estimate (EPS forecast of ($4.43)), which is informational for longer-term modeling but not a catalyst on its own. MarketBeat
• Negative Sentiment: Offsetting the upgrades, HC Wainwright sharply lowered near- and multi-year EPS forecasts across Q1–Q4 2026 and FY2026–FY2029 (e.g., FY2026 cut to ($10.32) from ($4.25); FY2027–FY2029 also pushed materially lower), while retaining a Buy rating and $28 PT — these large downside revisions imply greater near-term dilution, higher cash burn or program changes and represent a negative earnings/cash-flow signal investors should model into valuations. MarketBeat – Estimates

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.